Merck & Co.’s Global Health Innovation Fund and Kae Capital joined the Series D funding round, along with other existing investors including Novo Holdings, Health Quad and TeamFund, the startup said in a statement Monday. The company plans to use the proceeds to expand in the U.S. and other markets, improve its generative AI foundation models and fund acquisitions.
The Mumbai-based startup’s products use artificial intelligence to help identify and manage critical diseases at more than 3,000 imaging centers in over 90 countries. The company, founded in 2016, claims its solutions outperform human radiologists and physicians in diagnosing diseases such as tuberculosis, lung cancer and stroke. Several of its products are cleared for use by regulators in the United States and the European Union.
AI is helping to overcome obstacles in healthcare, said Prashant Warier, co-founder and CEO of Qure.AI. The technology is increasingly being used in areas such as drug discovery, patient management in hospitals and surgical robots.
Discover the stories that interest you
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.